Functional cure of chronic hepatitis B-hope or hype?  

作　　者：Gautam Ray 

机构地区：[1]Gastroenterology Unit,Department of Medicine,B.R.Singh Hospital,Kolkata 700014,West Bengal,India

出　　处：《World Journal of Hepatology》2024年第9期1199-1205,共7页世界肝病学杂志（英文）

摘　　要：Chronic hepatitis B constitutes a substantial disease burden worldwide.The steps advocated by the World Health Organization in 2016 to eradicate hepatitis B by 2030 has failed to achieve significant progress,especially with respect to immu-nization coverage and linkage to care.The lack of governmental and public awar-eness regarding the long-term implications of hepatitis B burden cause under-funding of developmental projects.The presently approved treatment modalities have limited efficacy in complete viral eradication,hence the need for newer molecules to achieve functional cure(sustained undetectable hepatitis B surface antigen(HBsAg)and hepatitis B virus DNA in peripheral blood after a finite period of therapy).However,preliminary results from trials of novel therapies show their inadequacy to achieve this end by themselves but better performance with a low baseline serum HBsAg with nucleos(t)ide analogues(NA)treatment which need to be combined with/without pegylated interferon as an immu-nomodulator.Such therapy is limited by cost and adverse events and need to show incremental benefit over the standard of care(long-term NA therapy)with respect to efficacy and drug toxicities,making the development process tenuous.Thus,while such therapies continue to be tested,strategies should still focus on prevention of transmission by non-pharmaceutical measures,vaccination and increasing linkage to care.

关 键 词：Hepatitis B DRUGS Clinical trial THERAPY Novel therapies Functional cure 

分 类 号：R512.62[医药卫生—内科学]